A Phase III, Multicentre, Randomized, Observer Blind, Parallel Group, Three Arms, Controlled Clinical Trial to Evaluate the Efficacy and Safety of Topically Applied Calcipotriol/AKVANO 50 μg/g Cutaneous Solution Against Calcipotriol Ointment 50 Micrograms/g, Sandoz and Placebo in Patients With Mild to Moderate Plaque Psoriasis

This study is a Phase III, multicentre, randomized, observer blind, parallel group, three arms, controlled clinical trial to evaluate the efficacy and safety of topically applied Calcipotriol/AKVANO 50 μg/g cutaneous solution against Calcipotriol Ointment 50 micrograms/g, Sandoz and placebo in patients with mild to moderate plaque psoriasis

开始日期2018-10-03

申办/合作机构

Cadila Pharmaceuticals Ltd.

NCT03469336

/ Completed临床1期

A PHASE 1, RANDOMIZED, DOUBLE-BLIND, VEHICLE AND ACTIVE COMPARATOR-CONTROLLED, PSORIASIS PLAQUE TEST STUDY TO ASSESS SAFETY, TOLERABILITY, AND PSORIATIC SKIN INFILTRATE THICKNESS FOLLOWING REPEATED, TOPICAL DOSES OF PF-06763809 SOLUTION IN SUBJECTS WITH MILD TO MODERATE CHRONIC PLAQUE PSORIASIS

The study is a randomized, double blinded, vehicle and active comparator controlled, multiple dose study in subjects with chronic plaque psoriasis. The study will have approximately 15 completers. Each subjects will receive three different topical doses of PF 06763809, PF 06763809 vehicle, and two active comparators. These will be applied to six different treatment fields for 18 days. The total duration of participation in the study will be approximately 7 weeks (minimum) to approximately 11 weeks (maximum), including the interval from Screening to the Follow up phone call visit.

开始日期2018-04-24

申办/合作机构

Pfizer Inc.

NCT01007591

/ Completed临床3期

Calcipotriol Plus Hydrocortisone in Paediatric Patients (Aged 6 to 17 Years) With Psoriasis Vulgaris on the Face and on the Intertriginous Areas

An international, multi-centre, prospective, randomised, double-blind, active-controlled, 2-arm, parallel group, 8-week, phase 3 clinical study in paediatric patients (aged 6 to 17 years) with psoriasis vulgaris on the face and on the intertriginous areas

开始日期2009-10-01

申办/合作机构

Leo Pharma, Inc.

100 项与卡泊三醇/氢化可的松相关的临床结果

登录后查看更多信息

100 项与卡泊三醇/氢化可的松相关的转化医学

登录后查看更多信息

100 项与卡泊三醇/氢化可的松相关的专利（医药）

登录后查看更多信息

100 项与卡泊三醇/氢化可的松相关的药物交易

登录后查看更多信息

研发状态

10 条进展最快的记录,

后查看更多信息

适应症	最高研发状态	国家/地区	公司	日期
寻常性银屑病	临床3期	加拿大	Leo Pharma, Inc.	2008-02-01
寻常性银屑病	临床3期	法国	Leo Pharma, Inc.	2008-02-01
寻常性银屑病	临床3期	英国	Leo Pharma, Inc.	2008-02-01
银屑病	临床3期	欧盟	LEO Pharma A/S	-
银屑病	临床3期	加拿大	LEO Pharma A/S	-
银屑病	临床3期	法国	LEO Pharma A/S	-

登录后查看更多信息

临床结果

适应症

分期

评价

查看全部结果

研究	分期	人群特征	评价人数	分组	结果	评价	发布日期


NCT01007591 (CTgov)	临床3期	寻常性银屑病	40	LEO 80190 (LEO 80190 Ointment)	糧醖構壓簾壓簾獵膚選(餘願憲窪鬱襯糧壓願網) = 壓衊顧膚壓窪築餘築築夢鹽衊網獵淵遞鬱廠淵 (膚餘餘鹽鬱積膚獵繭繭, 51.1) 更多	-	2019-01-15
				Hydrocortisone (Hydrocortisone 10 mg/g Ointment)	糧醖構壓簾壓簾獵膚選(餘願憲窪鬱襯糧壓願網) = 憲簾膚夢積繭簾選簾壓夢鹽衊網獵淵遞鬱廠淵 (膚餘餘鹽鬱積膚獵繭繭, 59.2) 更多
NCT00640822 (CTgov)	临床3期	寻常性银屑病	782	Calcipotriol plus hydrocortisone ointment (Calcipotriol Plus Hydrocortisone Ointment)	廠艱願鏇膚繭醖鹽網艱 = 觸選齋鏇觸製鹽願襯簾鹽糧壓餘憲壓簾鏇顧顧 (衊壓窪鹹衊鹹選鏇網醖, 顧鹹鏇窪廠製構鬱憲憲 ~ 衊膚網艱糧網遞積積遞) 更多	-	2010-12-21
				Calcipotriol plus hydrocortisone ointment vehicle (Calcipotriol Plus Hydrocortisone Ointment Vehicle)	廠艱願鏇膚繭醖鹽網艱 = 鏇餘鬱淵範鏇壓鏇獵蓋鹽糧壓餘憲壓簾鏇顧顧 (衊壓窪鹹衊鹹選鏇網醖, 壓衊網餘壓憲鬱衊願繭 ~ 顧製簾淵網製鹹獵繭網) 更多